110 related articles for article (PubMed ID: 34872103)
1. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.
Lyski ZL; Kim MS; Xthona Lee D; Raué HP; Raghunathan V; Griffin J; Ryan D; Brunton AE; Curlin ME; Slifka MK; Messer WB; Spurgeon SE
Blood Adv; 2022 Feb; 6(4):1207-1211. PubMed ID: 34872103
[No Abstract] [Full Text] [Related]
2. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
[No Abstract] [Full Text] [Related]
3. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
4. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren HG; Hansson L; Österborg A
Haematologica; 2022 Apr; 107(4):1000-1003. PubMed ID: 35045694
[No Abstract] [Full Text] [Related]
5. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Mellinghoff SC; Robrecht S; Mayer L; Weskamm LM; Dahlke C; Gruell H; Vanshylla K; Schlösser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
Leukemia; 2022 Feb; 36(2):562-565. PubMed ID: 34937858
[No Abstract] [Full Text] [Related]
7. Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients-Room for Improvement and Much to Learn.
Hill JA
JAMA Netw Open; 2021 Sep; 4(9):e2127454. PubMed ID: 34519771
[No Abstract] [Full Text] [Related]
8. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
[TBL] [Abstract][Full Text] [Related]
9. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status.
Demircan K; Chillon TS; Sun Q; Heller RA; Klingenberg GJ; Hirschbil-Bremer IM; Seemann P; Diegmann J; Bachmann M; Moghaddam A; Schomburg L
Redox Biol; 2022 Apr; 50():102242. PubMed ID: 35139480
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Mellinghoff SC; Mayer L; Robrecht S; Weskamm LM; Dahlke C; Gruell H; Schlotz M; Vanshylla K; Schloser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
Haematologica; 2022 Oct; 107(10):2480-2484. PubMed ID: 35734927
[No Abstract] [Full Text] [Related]
13. Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
Blixt L; Gao Y; Wullimann D; Murén Ingelman-Sundberg H; Muschiol S; Healy K; Bogdanovic G; Pin E; Nilsson P; Kjellander C; Grifoni A; Sette A; Sällberg Chen M; Ljunggren HG; Buggert M; Hansson L; Österborg A
Blood; 2022 Dec; 140(22):2403-2407. PubMed ID: 36150168
[No Abstract] [Full Text] [Related]
14. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.
Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
Kidney Int; 2021 Dec; 100(6):1334-1335. PubMed ID: 34656642
[No Abstract] [Full Text] [Related]
15. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
J Infect; 2021 Aug; 83(2):e4-e5. PubMed ID: 34214516
[No Abstract] [Full Text] [Related]
16. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
17. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
19. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
20. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
